Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers
Cells · 2024
DOI: 10.3390/cells13242087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Sara Manore und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Cytokine Receptor gp130, Triple Negative Breast Neoplasms, Ketoconazole, Indoles. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Defense, NCI NIH HHS, MetaVivor.
Abstract (Originalsprache)
Breast cancer stem cells (CSCs) are resistant to most cancer therapeutics and contribute to tumor recurrence and metastasis. Two breast CSC-promoting transcription factors, truncated glioma-associated oncogene homolog 1 (tGLI1) and signal transducer and activator of transcription 3 (STAT3), have been reported to be frequently co-expressed in HER2-enriched breast cancer and triple-negative breast cancer (TNBC), undergo protein-protein interactions for gene regulation and activation, and functionally cooperate to promote breast CSCs. STAT3 can be activated by activated interleukin-6 receptor/glycoprotein-130 (IL-6R/GP130). Co-targeting of tGLI1 and IL-6R/GP130 has not been investigated in breast cancer or any tumor type. Here, we report that tGLI1 and GP130 are co-overexpressed in the majority of HER2-enriched breast cancers and TNBCs at 53.8% and 44.4%, respectively. tGLI1+IL-6/IL-6R/GP130 signaling is frequently co-enriched and co-activated in HER2-enriched breast cancer and TNBC when compared to luminal subtypes. tGLI1+GP130 co-overexpression strongly promotes CSCs of HER2-enriched breast cancer and TNBC. FDA-approved tGLI1 inhibitor Ketoconazole and GP130 inhibitor Bazedoxifene synergize against breast cancer proliferation and CSC phenotypes in vitro and reduce TNBC tumor growth and metastatic burden in vivo. Our study demonstrates, for the first time, that co-targeting tGLI1 and IL-6R/GP130/STAT3 signaling pathways is synergistic against HER2-enriched breast cancer and TNBC, warranting future clinical investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Wake Forest Graduate School of Biomedical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
- Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
- Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
ORCID-Profile: Chuling Zhuang, Mariana K Najjar, Grace L Wong, Jiayuh Lin, Hui-Wen Lo
Förderung
- Department of Defense
- NCI NIH HHS
- MetaVivor
- NIH HHS
- DoD
- NIH
Zitieren
APA
Manore, S., Zhuang, C., Najjar, M. K., Wong, G. L., Bindal, S., Watabe, K., Lin, J., & Lo, H. W. (2024). Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells. https://doi.org/10.3390/cells13242087
Vancouver
Manore S, Zhuang C, Najjar MK, Wong GL, Bindal S, Watabe K, et al. Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers. Cells. 2024. doi:10.3390/cells13242087
BibTeX
@article{Manore2024,
author = {Manore, Sara and Zhuang, Chuling and Najjar, Mariana K and Wong, Grace L and Bindal, Shivani and Watabe, Kounosuke and Lin, Jiayuh and Lo, Hui-Wen},
title = {Co-Inhibition of tGLI1 and GP130 Using FDA-Approved Ketoconazole and Bazedoxifene Is Synergistic Against the Growth and Metastasis of HER2-Enriched and Triple-Negative Breast Cancers},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13242087}
}
EUVIMED